Clinical trials: Philadelphia-Negative ALL, open to volunteers
Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial
This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 32 adult patients with newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL).
- Trial name
- Ph- ALL-2026 (NCT07643103)
- Testing
- Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab
- Volunteers
- 32 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt-Like Lymphoma With 11q Aberration, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- Trial name
- NCT01371630
- Testing
- Blinatumomab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia
ALL Backbone in AYAs
The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs).
- Conditions
- Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
- Trial name
- NCT07227584
- Testing
- Blinatumomab, Oncaspar, Cyclophosphamide
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Dana-Farber Cancer Institute
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
This is a single-arm, prospective, phase 2 clinical trial evaluating the improvement of survival outcomes of blinatumomab combined with chemotherapy as a full-course treatment regimen in patients with newly diagnosed Philadelphia…
- Trial name
- FLOW (NCT07564453)
- Testing
- Blinatumomab, Induction Chemotherapy, Hyper-CVAD
- Where
- China
- Volunteers
- 101 people
- Sponsor
- The First Affiliated Hospital of Soochow University
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase II trial tests the safety, side effects, and effectiveness of asparaginase Erwinia chrysanthemi during induction chemotherapy followed by consolidation chemotherapy in treating high-risk adults with newly diagnosed…
- Trial name
- NCT06918431
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- City of Hope Medical Center